Faster global financial news!
CVS Health
-
CVS Health (CVS) shares rose 3.7% on Tuesday after Jefferies reiterated a Buy rating with a $120 price target.
Jefferies analyst Brian Tanquilut reiterated a "Buy" rating on CVS Health with a $120 price target, implying a 28% upside from Monday's closing price. The analyst named CVS as one of his top picks, no
-
CVS Health stock has risen over 18% year-to-date, outperforming the S&P 500, with Wall Street analysts projecting a further 22% upside to a consensus target of $114.59 per share.
The pharmacy chain's strong performance is attributed to two consecutive quarters of estimates-beating earnings in Q1 and Q2 2026, where it topped revenue and profitability consensus. Notably, its non
-
CVS Health shares dip about 6% after company issues early warnings for 2027, citing expected decline in Caremark membership and 340B drug-discount program pressures
Despite handily beating Wall Street’s expectations for the most recent quarter and raising its 2026 earnings guidance, the healthcare giant's stock fell due to its unusually early commentary on 2027.
-
CVS Health (CVS) shares rose 3.7% on Tuesday after Jefferies reiterated a Buy rating with a $120 price target.
Jefferies analyst Brian Tanquilut reiterated a "Buy" rating on CVS Health with a $120 price target, implying a 28% upside from Monday's closing price. The analyst named CVS as one of his top picks, no
-
CVS Health stock has risen over 18% year-to-date, outperforming the S&P 500, with Wall Street analysts projecting a further 22% upside to a consensus target of $114.59 per share.
The pharmacy chain's strong performance is attributed to two consecutive quarters of estimates-beating earnings in Q1 and Q2 2026, where it topped revenue and profitability consensus. Notably, its non
-
CVS Health shares dip about 6% after company issues early warnings for 2027, citing expected decline in Caremark membership and 340B drug-discount program pressures
Despite handily beating Wall Street’s expectations for the most recent quarter and raising its 2026 earnings guidance, the healthcare giant's stock fell due to its unusually early commentary on 2027.
- No data
CVS Health
24H Trending
-
1
AI data center company Nscale has publicly filed for a U.S. IPO, seeking to raise up to $3 billion. NVIDIA holds over 5% of its shares, and it has secured a $45 billion lease commitment from Anthropic.
-
2
Barclays: The First Wave of Physical AI Disruption May Not Be Humanoid, Specialized Robots Are Superior
-
3
Barclays: Humanoid robot computing power demand is mainly concentrated in edge AI, with limited but significant incremental growth for data centers.
-
4
Vantora (formerly UP.Labs) raised $100M, focusing on physical AI startups for industrial corporations
-
5
California Governor Signs Executive Order to Strengthen AI Regulation, Evaluate Setting Up AI "Emergency Kill Switch," Criticizes Trump Administration as "Sleepwalking"
-
6
UBS raises AI capital expenditure forecast: Nearing $1 trillion by 2026, with 90% of the increase driven by memory price hikes
-
7
OpenAI's new model, Astra, has captured 13% of enterprise AI spending within two weeks of its launch, prompting Anthropic to consider an early release of its new model to compete.
-
8
The dollar had its strongest week since June after the Federal Reserve's rate hike, with the Bloomberg Dollar Spot Index rising 1.1% this week.
-
9
Lookonchain Monitoring: A whale associated with Matrixport deposited 1,000 BTC, worth $81.06 million, to Binance.
-
10
Citibank Analysis: The Bank of Japan's dovish dissent and the Federal Reserve's rate hikes will accelerate its rate-hiking process, bringing forward the terminal rate achievement to July 2027.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
